Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Interest & Investment Income (2016 - 2025)

Voyager Therapeutics' Interest & Investment Income history spans 11 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 47.15% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $10.6 million, down 42.07%, while the annual FY2025 figure was $10.6 million, 42.07% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $2.1 million at Voyager Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.9 million in Q2 2024 and bottomed at -$643000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $2.2 million (2025), against an average of $2.1 million.
  • The largest annual shift saw Interest & Investment Income plummeted 893.83% in 2021 before it skyrocketed 5912.9% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at -$643000.0 in 2021, then surged by 251.79% to $976000.0 in 2022, then skyrocketed by 223.16% to $3.2 million in 2023, then increased by 26.63% to $4.0 million in 2024, then tumbled by 47.15% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Interest & Investment Income are $2.1 million (Q4 2025), $2.4 million (Q3 2025), and $2.8 million (Q2 2025).